Literature DB >> 26754286

Plasma levels of F-actin and F:G-actin ratio as potential new biomarkers in patients with septic shock.

Justin B Belsky1, Daniel C Morris2, Ralph Bouchebl3, Michael R Filbin1, Kevin R Bobbitt4, Anja K Jaehne2,5, Emanuel P Rivers2.   

Abstract

OBJECTIVE: To compare plasma levels of F-actin, G-actin and thymosin beta 4 (TB4) in humans with septic shock, noninfectious systemic inflammatory response syndrome (SIRS) and healthy controls.
RESULTS: F-actin was significantly elevated in septic shock as compared with noninfectious SIRS and healthy controls. G-actin levels were greatest in the noninfectious SIRS group but significantly elevated in septic shock as compared with healthy controls. TB4 was not detectable in the septic shock or noninfectious SIRS group above the assay's lowest detection range (78 ng/ml).
CONCLUSIONS: F-actin is significantly elevated in patients with septic shock as compared with noninfectious SIRS. F-actin and the F:G-actin ratio are potential biomarkers for the diagnosis of septic shock.

Entities:  

Keywords:  Actin; F-actin; G-actin; actin binding protein; coronary artery bypass graft; septic shock; thymosin beta 4

Mesh:

Substances:

Year:  2016        PMID: 26754286     DOI: 10.3109/1354750X.2015.1126646

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  3 in total

Review 1.  Thymosin beta 4 regulation of actin in sepsis.

Authors:  Justin B Belsky; Emanuel P Rivers; Michael R Filbin; Patty J Lee; Daniel C Morris
Journal:  Expert Opin Biol Ther       Date:  2018-03-06       Impact factor: 4.388

2.  Novel Damage Biomarkers of Sepsis-Related Acute Kidney Injury.

Authors:  Dániel Ragán; Zoltán Horváth-Szalai; Balázs Szirmay; Diána Mühl
Journal:  EJIFCC       Date:  2022-04-11

Review 3.  Periodontitis-Derived Dark-NETs in Severe Covid-19.

Authors:  Ljubomir Vitkov; Jasmin Knopf; Jelena Krunić; Christine Schauer; Janina Schoen; Bernd Minnich; Matthias Hannig; Martin Herrmann
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.